Literature DB >> 8700880

Betidamino acids: versatile and constrained scaffolds for drug discovery.

J E Rivier1, G Jiang, S C Koerber, J Porter, L Simon, A G Craig, C A Hoeger.   

Abstract

Betidamino acids (a contraction of "beta" position and "amide") are N'-monoacylated (optionally, N'-monoacylated and N-mono- or N,N'-dialkylated) aminoglycine derivatives in which each N'acyl/alkyl group may mimic naturally occurring amino acid side chains or introduce novel functionalities. Betidamino acids are most conveniently generated on solid supports used for the synthesis of peptides by selective acylation of one of the two amino functions of orthogonally protected aminoglycine(s) to generate the side chain either prior to or after the elongation of the main chain. We have used unresolved Nalpha-tert-butyloxycarbonyl-N'alpha-fluorenylmethoxycarbonyl++ + aminoglycine, and Nalpha-(Nalpha-methyl)-tert-butyloxycarbonyl-N'alpha-fluo renylmethoxycarbonyl aminoglycine as the templates for the introduction of betidamino acids in Acyline [Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph(Ac)-D4Aph(A c)-Leu-Ilys-Pro-DAla-NH2, where 2Nal is 2-naphthylalanine, 4Cpa is 4-chlorophenylalanine, 3Pal is 3-pyridylalanine, Aph is 4-aminophenylalanine, and Ilys is Nepsilon-isopropyllysine], a potent gonadotropin-releasing hormone antagonist, in order to test biocompatibility of these derivatives. Diasteremneric peptides could be separated in most cases by reverse-phase HPLC. Biological results indicated small differences in relative potencies (<5-fold) between the D and L nonalkylated betidamino acid-containing Acyline derivatives. Importantly, most betide diastereomers were equipotent with Acyline. In an attempt to correlate structure and observed potency, Ramachandran-type plots were calculated for a series of betidamino acids and their methylated homologs. According to these calculations, betidamino acids have access to a more limited and distinct number of conformational states (including those associated with alpha-helices, beta-sheets, or turn structures), with deeper minima than those observed for natural amino acids.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8700880      PMCID: PMC39904          DOI: 10.1073/pnas.93.5.2031

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  8 in total

1.  Derivation of force fields for molecular mechanics and dynamics from ab initio energy surfaces.

Authors:  J R Maple; U Dinur; A T Hagler
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 2.  Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective.

Authors:  M J Karten; J E Rivier
Journal:  Endocr Rev       Date:  1986-02       Impact factor: 19.871

3.  Ihibition of the pre-ovulatory proestrous gonadotropin surge, ovulation and pregnancy with a peptide analogue of luteinizing hormone releasing hormone.

Authors:  A Corbin; C W Beattie
Journal:  Endocr Res Commun       Date:  1975

4.  Novel biopolymers for drug discovery.

Authors:  E J Moran; T E Wilson; C Y Cho; S R Cherry; P G Schultz
Journal:  Biopolymers       Date:  1995       Impact factor: 2.505

5.  Design and synthesis of peptidomimetic inhibitors of HIV-1 protease and renin. Evidence for improved transport.

Authors:  A B Smith; R Hirschmann; A Pasternak; R Akaishi; M C Guzman; D R Jones; T P Keenan; P A Sprengeler; P L Darke; E A Emini
Journal:  J Med Chem       Date:  1994-01-21       Impact factor: 7.446

6.  Conformational effects of chiral alpha,alpha-dialkyl amino acids. I. C-terminal tetrapeptides of emerimicin containing alpha-ethylalanine.

Authors:  G R Marshall; J D Clark; J B Dunbar; G D Smith; J Zabrocki; A S Redlinski; M T Leplawy
Journal:  Int J Pept Protein Res       Date:  1988-12

7.  Peptoids: a modular approach to drug discovery.

Authors:  R J Simon; R S Kania; R N Zuckermann; V D Huebner; D A Jewell; S Banville; S Ng; L Wang; S Rosenberg; C K Marlowe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

8.  Gonadotropin-releasing hormone antagonists: novel members of the azaline B family.

Authors:  J E Rivier; G Jiang; J Porter; C A Hoeger; A G Craig; A Corrigan; W Vale; C L Rivier
Journal:  J Med Chem       Date:  1995-07-07       Impact factor: 7.446

  8 in total
  6 in total

1.  SST3-selective potent peptidic somatostatin receptor antagonists.

Authors:  J C Reubi; J C Schaer; S Wenger; C Hoeger; J Erchegyi; B Waser; J Rivier
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-05       Impact factor: 11.205

2.  Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.

Authors:  Manoj P Samant; Richard White; Doley J Hong; Glenn Croston; P Michael Conn; Jo Ann Janovick; Jean Rivier
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

3.  Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.

Authors:  Manoj P Samant; Jozsef Gulyas; Doley J Hong; Glenn Croston; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

4.  Combining flavin photocatalysis with parallel synthesis: a general platform to optimize peptides with non-proteinogenic amino acids.

Authors:  Jacob R Immel; Maheshwerreddy Chilamari; Steven Bloom
Journal:  Chem Sci       Date:  2021-06-30       Impact factor: 9.969

5.  Novel, potent, and radio-iodinatable somatostatin receptor 1 (sst1) selective analogues.

Authors:  Judit Erchegyi; Renzo Cescato; Christy Rani R Grace; Beatrice Waser; Véronique Piccand; Daniel Hoyer; Roland Riek; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

6.  Design and in vitro characterization of highly sst2-selective somatostatin antagonists suitable for radiotargeting.

Authors:  Renzo Cescato; Judith Erchegyi; Beatrice Waser; Véronique Piccand; Helmut R Maecke; Jean E Rivier; Jean Claude Reubi
Journal:  J Med Chem       Date:  2008-06-11       Impact factor: 7.446

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.